P95 BV ('P95'), a Belgium-based global company involved in clinical and epidemiology research solutions, with a focus on vaccines and infectious diseases, announced on Tuesday that it has acquired 4Clinics, a Belgium-based Contract Research Organisation (CRO) providing Data Management, Biostatistics, Scientific Writing, Regulatory Affairs and Clinical Operations services for clinical and epidemiological studies with expertise in vaccines, immunotherapeutics and medical devices.
The 4Clinic's team and operations have been completely integrated into the P95 group effective 1 July 2024
Thomas Verstraeten, P95 CEO, commented: "I am very excited to have the 4Clinics team as part of the P95 group. 4Clinics has a long history of supporting a wide range of customers across the globe, and like us, is well known for its expertise in vaccines and infectious disease. The knowledge and experience they bring, particularly in biometrics and medical writing, will significantly strengthen our capacity and enhance our ability to provide full-scale CRO services to our customers. Establishing ourselves in France will also enable us to better serve our Francophone clientele."
4Clinics president, Fabrice Degrez stated: "We are thrilled to start this strategic partnership in a competitive market where consolidation is key. By joining forces with P95, a like-minded partner sharing our Belgian roots, we are setting a robust foundation for innovation and enhanced capabilities. This collaboration underscores our commitment to excellence and ensures continuity and improved services for our customers. Together, we are dedicated to sustaining long-term advancements in our field."
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma